MindWalk Unveils B Cell Llama Platform for Next-Generation Nanobody Discovery
核心洞察
MindWalk Holdings Corp. (搜索) announced B Cell Llama (搜索)™, a new platform for discovering VHH nanobodies (搜索) designed specifically for bispecific antibodies and CAR-T cell therapies.
A peer-reviewed study in ACS Biomacromolecules demonstrated that multivalent nanobody formats achieved 10-25 times greater potency than monovalent forms and could overcome therapeutic resistance.
The platform integrates AI-guided precision through LensAI (搜索)™ technology across the entire discovery process, from target selection to multispecific construct evaluation.
MindWalk Holdings Corp. (搜索) has launched B Cell Llama (搜索)™, a nanobody discovery platform targeting the rapidly expanding bispecific antibody and cell therapy markets. The platform focuses on VHH nanobodies (搜索), single-domain antibody fragments that serve as molecular building blocks for next-generation therapeutics. With bispecific antibody sales projected to reach $50 billion by 2030 and the broader cell therapy market adding tens of billions more, the platform addresses a critical need for improved starting materials in drug development.
Peer-Reviewed Validation Demonstrates Enhanced Potency
The platform announcement is supported by a study published in Biomacromolecules by the American Chemical Society in 2026. Conducted through a grant-funded collaboration between MindWalk, Eindhoven University of Technology (搜索), and Radboud University Medical Center, the research revealed three key findings about modular VHH design capabilities.
Nanobodies displayed in multivalent formats achieved sub-nanomolar potency, demonstrating 10 to 25 times greater activity than the same nanobody in monovalent form. This potency amplification through assembly represents a significant advancement in therapeutic efficacy potential.
The study also demonstrated that modular reconfiguration can overcome therapeutic resistance. A trivalent VHH construct successfully neutralized variants that escaped all monovalent formats and outperformed approved antibody therapies. This finding suggests that rational reassembly of identical building blocks can restore activity where single agents fail.
Novel Immune-Priming Mechanism Identified
Perhaps most significantly, the research identified a potential immune-priming effect. VHH-nanoparticle complexes were preferentially internalized by immune cells associated with long-term immune memory. This discovery raises the possibility that certain VHH formats may not only neutralize targets but also help the immune system recognize them in future encounters.
The study produced an additional finding relevant to AI-guided drug discovery: the molecule with the strongest binding affinity delivered zero functional activity. This observation challenges conventional discovery workflows that rely heavily on binding metrics for candidate selection and supports the functional prioritization approach used by LensAI (搜索)™.
AI-Integrated Discovery Platform
B Cell Llama (搜索)™ builds on MindWalk's proven B Cell Select (搜索)® infrastructure, extending the technology from rabbit-derived antibodies to llama-derived VHH nanobodies (搜索). The platform captures nanobodies directly from naturally matured immune repertoires, accessing sequence diversity that synthetic display libraries cannot replicate and that genetically constrained transgenic platforms structurally limit.
"VHH nanobodies (搜索) solve the molecular engineering problem that has made bispecific and multispecific drug development so difficult for so long," said Dr. Jennifer Bath, Chief Executive Officer of MindWalk Holdings Corp. (搜索) "B Cell Llama (搜索)™ extends our flagship B Cell Select (搜索)® platform into the distinct biology of llama-derived single-domain antibodies, adding a dedicated VHH capability to the broader MindWalk ecosystem that has supported the advancement of over 15 molecules to the clinic across our technologies."
The platform integrates LensAI (搜索)™ technology across the full workflow, from immunogen design through candidate triage, multispecific construct modeling, and immunogenicity assessment. This AI-guided approach enables target selection before immunization begins, candidate triaging by predicted function, and in silico evaluation of multispecific constructs before laboratory construction.
Broader Pipeline Context
B Cell Llama (搜索)™ represents one expression of MindWalk's bio-native AI strategy, which is advancing programs across multiple therapeutic areas. Current programs include dengue (搜索) targeting all four serotypes and advancing to manufacturing, universal influenza (搜索) with conserved cross-strain target identification, GLP-1 (搜索) and longevity therapeutics featuring a first-in-class dual-pathway regimen with initiated IP protection, and ALK-1 for oncology (搜索) and rare disease applications.
The study was supported by Health Holland under Project LSHM20078 within the Eureka Program, with MindWalk holding first right to protect and commercialize jointly generated intellectual property. This strategic positioning provides the company with exclusive commercialization opportunities for the collaborative research outcomes.